Meta-Analysis on Statin Use and Colorectal Cancer Survival Outcomes

A systematic review and meta-analysis of 25 observational studies involving 179,979 colorectal cancer patients. The study, authored by Gang Li and published on figshare in 2026, analyzes the association between statin use and patient survival outcomes, including all-cause and cancer-specific mortality. It employs hazard ratios with 95% confidence intervals from a random-effects model.

Use Cases

• Assessing the association between statin use and all-cause mortality (ACM) in colorectal cancer patients based on pooled hazard ratios.
• Evaluating the impact of pre-diagnosis versus post-diagnosis statin use on cancer-specific mortality (CSM) based on the study's subgroup analysis.
• Investigating the lack of significant association between statin use and disease-free mortality (DFM) or recurrence-free mortality (RFM) reported in the results.

Strengths

• Analysis is based on a large pooled sample of 179,979 patients from 25 studies.
• Results provide specific hazard ratios and confidence intervals for multiple survival outcomes (e.g., ACM: HR 0.80, 95% CI 0.74-0.86).
• Includes a pre-registered systematic review protocol (INPLASY2025110064).

Limitations

• The primary data file is a 531.3 KB DOCX document; the underlying tabular data for the meta-analysis is not directly accessible.
• Row count and column-level documentation for any underlying data are unknown.
• The dataset's scope is limited to the aggregated results of the meta-analysis.

Provenance

Source

figshare, authored by Gang Li.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Cochrane Library, and Web of Science up to October 31, 2025.

Time Range

Studies included from database inception until October 31, 2025.

Freshness

Last updated 2026-03-18 05:21:15.